SCHEMBL3081869

SCHEMBL3081869

N#Cc1cc(F)ccc1N1CCN(C(=O)CCOc2ccc(F)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.52
POLB P06746 2/20 0.52
SMN1; SMN2 Q16637 5/20 0.50
ALDH1A1 P00352 4/20 0.50
HRH3 Q9Y5N1 2/20 0.50
LMNA P02545 2/20 0.50
MEN1 O00255 1/20 0.48
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
KMT2A Q03164 1/20 0.48
HSD17B10 Q99714 1/20 0.48
GAA P10253 4/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 1/20 0.47
HTT P42858 1/20 0.46
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.44
ENPP2 Q13822 1/20 0.43
THRB P10828 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3093363 0.94 MAPT (0.58) MAPTPOLBSMN1; SMN2ALDH1A1HRH3
SCHEMBL3077259 0.92 MAPT (0.48) MAPTPOLBSMN1; SMN2ALDH1A1HRH3
SCHEMBL3077623 0.90 MAPT (0.47) MAPTPOLBSMN1; SMN2ALDH1A1HRH3
SCHEMBL3091995 0.89 MAPT (0.57) MAPTPOLBSMN1; SMN2ALDH1A1HRH3
SCHEMBL3093276 0.82 MAPT (0.47) MAPTPOLBSMN1; SMN2ALDH1A1HRH3
SCHEMBL3089864 0.82 MAPT (0.47) MAPTPOLBSMN1; SMN2ALDH1A1HRH3
SCHEMBL3085630 0.82 NPC1 (0.55) MAPTPOLBSMN1; SMN2ALDH1A1HRH3
SCHEMBL3083281 0.81 MAPT (0.47) MAPTPOLBSMN1; SMN2ALDH1A1HRH3
SCHEMBL3090175 0.80 MAPT (0.50) MAPTPOLBSMN1; SMN2ALDH1A1HRH3
SCHEMBL3085560 0.79 NPC1 (0.61) MAPTPOLBSMN1; SMN2ALDH1A1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100227870-A1 Novel Compounds GLAXO GROUP LIMITED (GB) 2010-09-09 US claimed
EP-2164837-A1 NOVEL COMPOUNDS Glaxo Group Limited (GB) 2010-03-24 EP claimed
WO-2008152089-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-12-18 WO claimed
US-20100227870-A1 Novel Compounds GLAXO GROUP LIMITED (GB) 2010-09-09 US disclosed
EP-2164837-A1 NOVEL COMPOUNDS Glaxo Group Limited (GB) 2010-03-24 EP disclosed
WO-2008152089-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227870-A1 Novel Compounds GRM5, GRIK5, GRM1 MAPT 1435/4885POLB 4651/4885SMN1; SMN2 1875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.